Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Reproductive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm

Cancer Family

Reproductive System Neoplasm

CI-CAN-00000338Explore in graph →

Non-malignant3,042 active trials38 approved drugs197 evidence items

NCIt: C3674

Overview
Statistics
Survival
Genomics65
Variants & evidence197
Drugs58
Trials13672
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (625)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 476–500 of 625 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
· N Engl J Med · 2016 · PMID 27717299 · validated civic_curation pubmed
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
· Nat Genet · 2014 · PMID 24658004 · validated cbioportal_study pubmed
Advanced ovarian cancer: what should be the standard of care?
· J Gynecol Oncol · 2013 · PMID 23346317 · validated civic_curation pubmed
Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
· Cancer · 2010 · PMID 20336784 · validated civic_curation pubmed
The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary.
· Mod Pathol · 2010 · PMID 20693978 · validated civic_curation pubmed
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
· Br J Cancer · 2007 · PMID 17700571 · validated civic_curation pubmed
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
· N Engl J Med · 2015 · PMID 26510020 · validated civic_curation pubmed
XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.

Showing 476–500 of 625 publications

← Previous
1
…
19
20
21
…
25
Next →

· Gynecol Oncol · 2006 · PMID 16875718 · validated civic_curation pubmed

ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.

· J Clin Oncol · 2009 · PMID 19470935 · validated civic_curation pubmed

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

· Am J Obstet Gynecol · 2005 · PMID 15746676 · validated civic_curation pubmed

Integrative clinical genomics of advanced prostate cancer.

· Cell · 2015 · PMID 26000489 · validated civic_curation pubmed

The association of Phosphatase and tensin homolog (PTEN) deletion and prostate cancer risk: A meta-analysis.

· Biomed Pharmacother · 2016 · PMID 27470558 · validated civic_curation pubmed

MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.

· Sci Rep · 2016 · PMID 27819322 · validated civic_curation pubmed

The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.

· Cancer Epidemiol Biomarkers Prev · 2015 · PMID 26108461 · validated civic_curation pubmed

Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.

· Oncotarget · 2016 · PMID 27626483 · validated civic_curation pubmed

Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

· Clin Cancer Res · 2001 · PMID 11595686 · validated civic_curation pubmed

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

· Cancer Discov · 2017 · PMID 28242752 · validated civic_curation pubmed

A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors.

· Mod Pathol · 2015 · PMID 26428316 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.

· Cancer Sci · 2015 · PMID 26250934 · validated civic_curation pubmed

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

· J Clin Oncol · 2019 · PMID 30865549 · validated civic_curation pubmed

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

· JAMA Oncol · 2016 · PMID 27262168 · validated civic_curation pubmed

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.

· JAMA Oncol · 2018 · PMID 29955787 · validated civic_curation pubmed

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· JCO Precis Oncol · 2025 · PMID 41100773 · validated civic_curation pubmed

Aurora kinases as prognostic biomarkers in ovarian carcinoma.

· Hum Pathol · 2009 · PMID 19157502 · validated civic_curation pubmed